ENvue Medical Seeks Stockholder Approval for Reverse Stock Split to Avoid Nasdaq Delisting

summarizeSummary

ENvue Medical calls a special stockholder meeting for August 14, 2026 to vote on a reverse stock split aimed at regaining Nasdaq compliance after receiving a delisting notice. The company faces immediate delisting risk because prior reverse splits disqualify it from the standard grace period.

check_boxKey Events · Corporate Governance and Compliance · FEED

• Reverse Stock Split Proposed

  Board seeks approval for a reverse stock split at a ratio between 1-for-2 and 1-for-50 to increase the stock price above $1.00 and regain Nasdaq compliance. The special meeting is set for August 14, 2026.

• Nasdaq Delisting Notice

  On July 10, 2026, Nasdaq notified the company that its stock had closed below $1.00 for 30 consecutive business days. The company is not eligible for the standard 180-day compliance period because it has already executed two reverse splits in the past year.

• Third Reverse Split in 18 Months

  The company previously executed a 1-for-11 reverse split on March 13, 2025 and a 1-for-10 reverse split on August 12, 2025. The cumulative ratio of prior splits is 1-for-110, and the new split could push the total above the 250-to-one threshold, triggering immediate delisting if the price falls below $1 again.

• Appeal to Stay Delisting

  The company intends to request a hearing before Nasdaq's Appeal Panel, which will stay any suspension or delisting action pending the panel's decision. There is no assurance the appeal will be successful.

auto_awesomeAnalysis · FEED · Industrial Applications And Services

ENvue Medical is fighting to stay on Nasdaq after receiving a delisting notice on July 10, 2026. The company is asking stockholders to approve a reverse stock split at a ratio between 1-for-2 and 1-for-50 at a special meeting on August 14, 2026. This is the third reverse split in 18 months — the company already executed a 1-for-11 split in March 2025 and a 1-for-10 split in August 2025. Because of those prior splits, Nasdaq has denied the standard 180-day compliance period, meaning the stock faces immediate delisting unless the split boosts the price above $1. The company will also appeal the delisting determination, which stays any suspension pending a hearing. With the stock at $0.47 and a market cap of just $2.8 million, the reverse split is a last-ditch effort to preserve the Nasdaq listing, which is critical for liquidity and access to capital.